All Articles

Nurse Navigator Amy Jo Pixley reveals how she organizes her day, prioritizes her work load, implements metrics, and cares for individual patients.

The authors examine and assess the effect of a nurse navigator home visit in reducing distress among women who have been newly diagnosed with breast cancer.

A psychological intervention called Managing Cancer and Living Meaningfully (CALM), specifically developed for people with advanced/metastatic cancer, reduced depressive symptoms and the chances of developing depression compared with usual care, according to results of a randomized trial presented at the 2017 Annual Meeting of the Multinational Association of Supportive Care in Cancer

At the 2017 Annual Meeting of the Multinational Association of Supportive Care in Cancer, Dr. Jeanne Carter shared research from her program at MSKDD to update attendees on current finding, newer assessment instruments, and clinical tools to identify sexual health concern in women with cancer.

In this Special Edition, we direct our attention to lung cancer and the positive impact navigators have had in this disease state.

In an effort to understand a day in the life of a thoracic navigator, we spent some time with Wendy Brooks, RN, ONN-CG. Ms Brooks obtained her certification as generalist oncology nurse navigator through the Academy of Oncology Nurse & Patient Navigators (AONN+) and was instrumental in the development of the AONN+ specialty certification exam in thoracic oncology.

To be effective, navigators are required to stay up to date on the constantly changing landscape of lung cancer care.

It has been proved that teamwork is vital in the battle against cancer. This is a fact that the Academy of Oncology Nurse & Patient Navigators (AONN+) and the American Cancer Society (ACS) recently validated when they entered into a National Alliance Partnership Program.

Osimertinib improves progression-free survival by 54% compared with standard first-line therapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented at the ESMO 2017 Congress in Madrid.

Durvalumab, a PD-L1 inhibitor, improved progression-free survival (PFS) by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) that did not progress after standard treatment with chemoradiotherapy, according to results presented at the ESMO 2017 Congress.